Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies

19Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Biomedical research devotes a huge effort to the development of efficient non-viral nano-vectors (NV) to improve the effectiveness of standard therapies. NVs should be stable, sustainable and biocompatible and enable controlled and targeted delivery of drugs. With the aim to foster the advancements of such devices, this review reports some recent results applicable to treat two types of pathologies, cancer and microbial infections, aiming to provide guidance in the overall design of personalized nanomedicines and highlight the key role played by peptides in this field. Additionally, future challenges and potential perspectives are illustrated, in the hope of accelerating the translational advances of nanomedicine.

Cite

CITATION STYLE

APA

Del Genio, V., Bellavita, R., Falanga, A., Hervé-Aubert, K., Chourpa, I., & Galdiero, S. (2022, June 1). Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics14061235

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free